FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3166273661> ?p ?o ?g. }

• W3166273661 endingPage "1044" @default.
• W3166273661 startingPage "1035" @default.
• W3166273661 abstract "Brentuximab vedotin (BV) was approved as a therapy for mycosis fungoides (MF) based on the ALCANZA trial. Little real-world data, however, are available.To evaluate the efficacy and safety of BV in patients with MF/Sézary Syndrome (SS) with variable CD30 positivity in a real-world cohort and to explore potential predictors of response.Data from 72 patients with MF/SS across nine EORTC (European Organization for Research and Treatment of Cancer) centres were included. The primary endpoint was to evaluate the proportion of patients with: overall response (ORR), ORR lasting over 4 months (ORR4), time to response (TTR), response duration (RD), progression-free survival (PFS) and time to next treatment (TTNT). Secondary aims included a safety evaluation and the association of clinicopathological features with ORR, RD and TTNT.All 72 patients had received at least one systemic treatment. ORR was achieved in 45 of 67; ORR4 in 28 of 67 with a median TTR of 8 weeks [interquartile range (IQR) 5·5-14] and with a median RD of 9 months (IQR 3·4-14). Median PFS was 7 months (IQR 2-12) and median TTNT was 30 days (6-157·5). Patient response, RD, PFS and TTNT were not associated with any clinicopathological characteristics. In the MF group, patients with stage IIB/III vs. IV achieved longer PFS and had a higher percentage of ORR4. There was a statistically significant association between large-cell transformation and skin ORR (P = 0·03). ORR4 was more frequently achieved in patients without lymph node involvement (P = 0·04).BV is an effective option for patients with MF/SS, including those with variable CD30 positivity, large-cell transformation, SS, longer disease duration and who have been treated previously with several therapies." @default.
• W3166273661 created "2021-06-22" @default.
• W3166273661 creator A5008364803 @default.
• W3166273661 creator A5008489591 @default.
• W3166273661 creator A5008492560 @default.
• W3166273661 creator A5012521997 @default.
• W3166273661 creator A5016870178 @default.
• W3166273661 creator A5016871162 @default.
• W3166273661 creator A5019172372 @default.
• W3166273661 creator A5027685440 @default.
• W3166273661 creator A5029467349 @default.
• W3166273661 creator A5040812031 @default.
• W3166273661 creator A5047138177 @default.
• W3166273661 creator A5057727897 @default.
• W3166273661 creator A5058782928 @default.
• W3166273661 creator A5066790760 @default.
• W3166273661 creator A5067165268 @default.
• W3166273661 creator A5068780868 @default.
• W3166273661 creator A5071547266 @default.
• W3166273661 creator A5072248667 @default.
• W3166273661 creator A5087576547 @default.
• W3166273661 date "2021-08-17" @default.
• W3166273661 modified "2023-10-18" @default.
• W3166273661 title "Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sézary syndrome with variable CD30 positivity*" @default.
• W3166273661 cites W1877715550 @default.
• W3166273661 cites W1967961740 @default.
• W3166273661 cites W1985984158 @default.
• W3166273661 cites W1998800560 @default.
• W3166273661 cites W2045009458 @default.
• W3166273661 cites W2060466778 @default.
• W3166273661 cites W2096455548 @default.
• W3166273661 cites W2096850086 @default.
• W3166273661 cites W2104425796 @default.
• W3166273661 cites W2105524669 @default.
• W3166273661 cites W2119799189 @default.
• W3166273661 cites W2139891818 @default.
• W3166273661 cites W2155256323 @default.
• W3166273661 cites W2171365282 @default.
• W3166273661 cites W2185330453 @default.
• W3166273661 cites W2339885660 @default.
• W3166273661 cites W2592527898 @default.
• W3166273661 cites W2601178524 @default.
• W3166273661 cites W2623658063 @default.
• W3166273661 cites W2735860324 @default.
• W3166273661 cites W2746829306 @default.
• W3166273661 cites W2764050266 @default.
• W3166273661 cites W2769841213 @default.
• W3166273661 cites W2893979018 @default.
• W3166273661 cites W2950510688 @default.
• W3166273661 cites W2974153076 @default.
• W3166273661 cites W2995362263 @default.
• W3166273661 cites W3119854835 @default.
• W3166273661 cites W3148985220 @default.
• W3166273661 doi "https://doi.org/10.1111/bjd.20588" @default.
• W3166273661 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34137025" @default.
• W3166273661 hasPublicationYear "2021" @default.
• W3166273661 type Work @default.
• W3166273661 sameAs 3166273661 @default.
• W3166273661 citedByCount "12" @default.
• W3166273661 countsByYear W31662736612021 @default.
• W3166273661 countsByYear W31662736612022 @default.
• W3166273661 countsByYear W31662736612023 @default.
• W3166273661 crossrefType "journal-article" @default.
• W3166273661 hasAuthorship W3166273661A5008364803 @default.
• W3166273661 hasAuthorship W3166273661A5008489591 @default.
• W3166273661 hasAuthorship W3166273661A5008492560 @default.
• W3166273661 hasAuthorship W3166273661A5012521997 @default.
• W3166273661 hasAuthorship W3166273661A5016870178 @default.
• W3166273661 hasAuthorship W3166273661A5016871162 @default.
• W3166273661 hasAuthorship W3166273661A5019172372 @default.
• W3166273661 hasAuthorship W3166273661A5027685440 @default.
• W3166273661 hasAuthorship W3166273661A5029467349 @default.
• W3166273661 hasAuthorship W3166273661A5040812031 @default.
• W3166273661 hasAuthorship W3166273661A5047138177 @default.
• W3166273661 hasAuthorship W3166273661A5057727897 @default.
• W3166273661 hasAuthorship W3166273661A5058782928 @default.
• W3166273661 hasAuthorship W3166273661A5066790760 @default.
• W3166273661 hasAuthorship W3166273661A5067165268 @default.
• W3166273661 hasAuthorship W3166273661A5068780868 @default.
• W3166273661 hasAuthorship W3166273661A5071547266 @default.
• W3166273661 hasAuthorship W3166273661A5072248667 @default.
• W3166273661 hasAuthorship W3166273661A5087576547 @default.
• W3166273661 hasConcept C119060515 @default.
• W3166273661 hasConcept C126322002 @default.
• W3166273661 hasConcept C143998085 @default.
• W3166273661 hasConcept C167135981 @default.
• W3166273661 hasConcept C203014093 @default.
• W3166273661 hasConcept C2776090121 @default.
• W3166273661 hasConcept C2777756187 @default.
• W3166273661 hasConcept C2777891184 @default.
• W3166273661 hasConcept C2778191690 @default.
• W3166273661 hasConcept C2779338263 @default.
• W3166273661 hasConcept C70905583 @default.
• W3166273661 hasConcept C71924100 @default.
• W3166273661 hasConcept C8891405 @default.
• W3166273661 hasConceptScore W3166273661C119060515 @default.
• W3166273661 hasConceptScore W3166273661C126322002 @default.
• W3166273661 hasConceptScore W3166273661C143998085 @default.

• next